Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary-Reference-Cited by-同舟云学术

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary

Published:2018-04 Issue:4 Volume:14 Page:247-249
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Brahmer Julie R.¹,Lacchetti Christina¹,Thompson John A.¹

Affiliation:

1. Johns Hopkins Kimmel Cancer Center, Baltimore, MD; American Society of Clinical Oncology, Alexandria, VA; University of Washington; and Fred Hutchinson Cancer Research Center, Seattle, WA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.18.00005

Reference2 articles.

1. Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer

Cited by 226 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2);Journal for ImmunoTherapy of Cancer;2024-08

2. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26

3. Autoimmune encephalitis followed by hemophagocytic lymph histiocytosis: a case report;Frontiers in Immunology;2024-07-22

4. Investigating risk factors and treatment options for severe, partially steroid responsive, and steroid-refractory checkpoint inhibitor pneumonitis;The Oncologist;2024-06-17